cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.8979785
title: Comparison of epidemiology and injury profile between vulnerable road users and motor vehicle occupants in road traffic fatalities

description: <b>Objective:</b> Road traffic injuries (RTIs) are a major global health issue causing a global burden of mortality and morbidity. Half of all fatalities on the world’s roads are vulnerable road users (VRUs). The targeted intervention strategies based on fatality analysis focusing on VRUs can effectively contribute to reducing RTIs. This study aimed to compare VRUs and motor vehicle occupants (MVOs) in terms of epidemiology and injury profile. <b>Methods:</b> We utilized a nationwide, prospective database of RTI-related mortality cases for patients who visited 23 emergency departments between January 2011 and December 2015. All fatalities due to RTIs in the prehospital phase or in-hospital were eligible, excluding patients with unknown mode of transport and those admitted to general wards. The primary and secondary outcomes were fracture injuries and visceral injuries diagnosed using the <i>International Classification of Diseases</i>, Tenth Revision (ICD-10). We compared fracture injuries between VRUs and MVOs using Abbreviated Injury Scale (AIS) 2− and 2+ classification. <b>Results:</b> Among a total 3,694 road traffic fatalities (RTFs), 43.3% were pedestrians, followed by MVOs (27.0%), motorcyclists (18.9), bicyclists (6.6%), and agricultural vehicle users (4.2%). The elderly (&gt;60 years old) accounted for 54.9% of VRU fatalities. RTFs occurred most frequently in the autumn and the VRU group and the MVO group showed significant differences in weekly and diurnal variation in RTFs. The injury severities (AIS 2+) of the head, neck, and thorax were significantly different between the 2 groups (<i>P</i> <b>Conclusions:</b> Elderly pedestrians should be targeted for decreases in RTFs, and road traffic safety interventions for VRUs should be made based on the analysis of temporal epidemiology and injury profiles of RTFs.
DOI: 10.6084/m9.figshare.8979785.v1
title: Comparison of epidemiology and injury profile between vulnerable road users and motor vehicle occupants in road traffic fatalities

description: <b>Objective:</b> Road traffic injuries (RTIs) are a major global health issue causing a global burden of mortality and morbidity. Half of all fatalities on the world’s roads are vulnerable road users (VRUs). The targeted intervention strategies based on fatality analysis focusing on VRUs can effectively contribute to reducing RTIs. This study aimed to compare VRUs and motor vehicle occupants (MVOs) in terms of epidemiology and injury profile. <b>Methods:</b> We utilized a nationwide, prospective database of RTI-related mortality cases for patients who visited 23 emergency departments between January 2011 and December 2015. All fatalities due to RTIs in the prehospital phase or in-hospital were eligible, excluding patients with unknown mode of transport and those admitted to general wards. The primary and secondary outcomes were fracture injuries and visceral injuries diagnosed using the <i>International Classification of Diseases</i>, Tenth Revision (ICD-10). We compared fracture injuries between VRUs and MVOs using Abbreviated Injury Scale (AIS) 2− and 2+ classification. <b>Results:</b> Among a total 3,694 road traffic fatalities (RTFs), 43.3% were pedestrians, followed by MVOs (27.0%), motorcyclists (18.9), bicyclists (6.6%), and agricultural vehicle users (4.2%). The elderly (&gt;60 years old) accounted for 54.9% of VRU fatalities. RTFs occurred most frequently in the autumn and the VRU group and the MVO group showed significant differences in weekly and diurnal variation in RTFs. The injury severities (AIS 2+) of the head, neck, and thorax were significantly different between the 2 groups (<i>P</i> <b>Conclusions:</b> Elderly pedestrians should be targeted for decreases in RTFs, and road traffic safety interventions for VRUs should be made based on the analysis of temporal epidemiology and injury profiles of RTFs.
DOI: 10.6084/m9.figshare.8979842.v2
title: Robertson and McClelland 2019

description: Data for Journal of Experimental Biology (2019) 222, jeb210963. doi:10.1242/jeb.210963
DOI: 10.6084/m9.figshare.8979644
title: Peruvian scholary journals indexed at SciELO, Scopus and ESCI-WoS on Google Scholar Metrics (July-2019)

description: Dataset is part current research around a thesis degree in Spanish intitled "Calidad editorial, impacto científico y visibilidad web de las revistas científicas de universidades peruanas". Includes two H-index metrics related about 40 scholary journals indexing at SciELO, Scopus, Emerging Sources Citation Index (WoS) acoording to Google Scholar Metrics 2019 updated on July, 2019.<br>
DOI: 10.6084/m9.figshare.8979644.v1
title: Peruvian scholary journals indexed at SciELO, Scopus and ESCI-WoS on Google Scholar Metrics (July-2019)

description: Dataset is part current research around a thesis degree in Spanish intitled "Calidad editorial, impacto científico y visibilidad web de las revistas científicas de universidades peruanas". Includes two H-index metrics related about 40 scholary journals indexing at SciELO, Scopus, Emerging Sources Citation Index (WoS) acoording to Google Scholar Metrics 2019 updated on July, 2019.<br>
DOI: 10.6084/m9.figshare.8977658
title: Effectiveness, safety, and methotrexate dose-tapering pattern over two years of treatment with adalimumab and ≥12 mg/week methotrexate for early rheumatoid arthritis: Results of the HAWK postmarketing surveillance study in Japan

description: <b>Objectives:</b> To investigate the long-term effectiveness, safety, and methotrexate (MTX) dose-tapering patterns in patients with rheumatoid arthritis (RA) receiving adalimumab plus high-dose MTX. <b>Methods:</b> In this prospective, postmarketing study (2012–2017), conducted at 128 sites in Japan, biologic-naïve patients with RA (duration ≤2 years) previously treated with MTX for ≥3 months, initiated treatment with adalimumab and MTX (≥12 mg/week). Effectiveness by Disease Activity Score in 28 joints using C-reactive protein (DAS28-CRP), safety, and MTX dose-tapering were assessed from baseline to 104 weeks. <b>Results:</b> In the effectiveness analysis set (<i>n</i> = 292), DAS28-CRP remission (&lt;2.6) was achieved in 92.3% (<i>n</i> = 120/130) of patients at week 104. The proportions of patients receiving MTX dose &lt;10 mg/week increased to 32.3% (<i>n</i> = 50/155) and ≥12 mg/week reduced to 52.9% (<i>n</i> = 82/155) by week 104. Per univariate regression analysis, MTX dose tapering was associated with longer adalimumab drug survival. Of 70 patients with joint X-rays available, 59 (84.3%) achieved Δ modified total Sharp score ≤1.0 at 104 weeks. In the safety analysis set (<i>n</i> = 300), 143 adverse drug reactions were reported in 92 patients (30.7%, non-serious; 24.7%, serious 8.7%). <b>Conclusion:</b> The long-term effectiveness and safety of adalimumab with high-dose MTX was confirmed in biologic-naïve patients with early RA in a real-world setting in Japan. <b>Clinical Trial Registration:</b> This study is registered at ClinicalTrials.gov (identifier: NCT01736189; retrospectively registered 29 November 2012, due to administrative reasons).
DOI: 10.6084/m9.figshare.8977664
title: Can real-life driving ability be predicted by the Maintenance of Wakefulness Test?

description: <b>Objective:</b> Drowsy driving is a profound road safety issue. In patients with excessive daytime sleepiness (EDS), the Maintenance of Wakefulness Test (MWT) is commonly used to evaluate driving ability. However, there is little evidence that MWT predicts driving performance, and several sleep latency cutoffs have been suggested. <b>Methods:</b> Based on a retrospective chart analysis of patients with an MWT and a driving ability assessment between January 2006 and November 2014, we identified 63 studies in 60 patients. The driving ability assessment judged the patients as qualified or disqualified for commercial driving. MWT latencies to 3 s of alpha activity, 3 s of drowsiness (microsleep), and sleep onset were compared between qualified and disqualified patients and their validity to identify driving qualification was evaluated. <b>Results:</b> Disqualified patients had shorter alpha, microsleep, and sleep latencies, but the latency distributions were widely overlapping. MWT accuracy to predict driving performance was poor: two thirds of short sleep latencies were false positives. Adding information from alpha and microsleep latencies added little extra accuracy. <b>Conclusions:</b> MWT results correlate poorly with driving performance in a 2-h test irrespective of sleep latency cutoff or added alpha/microsleep latency data. Better diagnostic tools are needed to evaluate driving performance in patients with EDS.
DOI: 10.6084/m9.figshare.8977664.v1
title: Can real-life driving ability be predicted by the Maintenance of Wakefulness Test?

description: <b>Objective:</b> Drowsy driving is a profound road safety issue. In patients with excessive daytime sleepiness (EDS), the Maintenance of Wakefulness Test (MWT) is commonly used to evaluate driving ability. However, there is little evidence that MWT predicts driving performance, and several sleep latency cutoffs have been suggested. <b>Methods:</b> Based on a retrospective chart analysis of patients with an MWT and a driving ability assessment between January 2006 and November 2014, we identified 63 studies in 60 patients. The driving ability assessment judged the patients as qualified or disqualified for commercial driving. MWT latencies to 3 s of alpha activity, 3 s of drowsiness (microsleep), and sleep onset were compared between qualified and disqualified patients and their validity to identify driving qualification was evaluated. <b>Results:</b> Disqualified patients had shorter alpha, microsleep, and sleep latencies, but the latency distributions were widely overlapping. MWT accuracy to predict driving performance was poor: two thirds of short sleep latencies were false positives. Adding information from alpha and microsleep latencies added little extra accuracy. <b>Conclusions:</b> MWT results correlate poorly with driving performance in a 2-h test irrespective of sleep latency cutoff or added alpha/microsleep latency data. Better diagnostic tools are needed to evaluate driving performance in patients with EDS.
DOI: 10.6084/m9.figshare.8977658.v1
title: Effectiveness, safety, and methotrexate dose-tapering pattern over two years of treatment with adalimumab and ≥12 mg/week methotrexate for early rheumatoid arthritis: Results of the HAWK postmarketing surveillance study in Japan

description: <b>Objectives:</b> To investigate the long-term effectiveness, safety, and methotrexate (MTX) dose-tapering patterns in patients with rheumatoid arthritis (RA) receiving adalimumab plus high-dose MTX. <b>Methods:</b> In this prospective, postmarketing study (2012–2017), conducted at 128 sites in Japan, biologic-naïve patients with RA (duration ≤2 years) previously treated with MTX for ≥3 months, initiated treatment with adalimumab and MTX (≥12 mg/week). Effectiveness by Disease Activity Score in 28 joints using C-reactive protein (DAS28-CRP), safety, and MTX dose-tapering were assessed from baseline to 104 weeks. <b>Results:</b> In the effectiveness analysis set (<i>n</i> = 292), DAS28-CRP remission (&lt;2.6) was achieved in 92.3% (<i>n</i> = 120/130) of patients at week 104. The proportions of patients receiving MTX dose &lt;10 mg/week increased to 32.3% (<i>n</i> = 50/155) and ≥12 mg/week reduced to 52.9% (<i>n</i> = 82/155) by week 104. Per univariate regression analysis, MTX dose tapering was associated with longer adalimumab drug survival. Of 70 patients with joint X-rays available, 59 (84.3%) achieved Δ modified total Sharp score ≤1.0 at 104 weeks. In the safety analysis set (<i>n</i> = 300), 143 adverse drug reactions were reported in 92 patients (30.7%, non-serious; 24.7%, serious 8.7%). <b>Conclusion:</b> The long-term effectiveness and safety of adalimumab with high-dose MTX was confirmed in biologic-naïve patients with early RA in a real-world setting in Japan. <b>Clinical Trial Registration:</b> This study is registered at ClinicalTrials.gov (identifier: NCT01736189; retrospectively registered 29 November 2012, due to administrative reasons).
DOI: 10.6084/m9.figshare.8977547
title: Working on working together. A systematic review on how healthcare professionals contribute to interprofessional collaboration

description: Professionals in healthcare are increasingly encouraged to work together. This has acted as a catalyst for research on interprofessional collaboration. Authors suggest developing interprofessional collaboration is not just the job of managers and policy makers; it also requires active contributions of professionals. Empirical understanding of whether professionals make such contributions and if so, how and why, remains fragmented. This systematic review of 64 studies from the past 20 years shows there is considerable evidence for professionals actively contributing to interprofessional collaboration. Although the evidence is limited, we can show they do so in three distinct ways: by <i>bridging</i> professional, social, physical and task-related <i>gaps</i>, by <i>negotiating overlaps</i> in roles and tasks, and by <i>creating spaces</i> to be able to do so. Professionals from different professions seem to make different contributions. Moreover, differences exist between collaborative settings and healthcare subsectors. We conclude by proposing a research agenda to advance our understanding of these contributions in theoretical, methodological and empirical ways.
DOI: 10.6084/m9.figshare.8977496
title: Supplemental tables for: Clinical and genetic characterization of 153 patients with persistent or transient congenital hyperinsulinism. Männistö JME et al. JCEM 2019.

description: Supplemental tables 1-4
DOI: 10.6084/m9.figshare.8977547.v1
title: Working on working together. A systematic review on how healthcare professionals contribute to interprofessional collaboration

description: Professionals in healthcare are increasingly encouraged to work together. This has acted as a catalyst for research on interprofessional collaboration. Authors suggest developing interprofessional collaboration is not just the job of managers and policy makers; it also requires active contributions of professionals. Empirical understanding of whether professionals make such contributions and if so, how and why, remains fragmented. This systematic review of 64 studies from the past 20 years shows there is considerable evidence for professionals actively contributing to interprofessional collaboration. Although the evidence is limited, we can show they do so in three distinct ways: by <i>bridging</i> professional, social, physical and task-related <i>gaps</i>, by <i>negotiating overlaps</i> in roles and tasks, and by <i>creating spaces</i> to be able to do so. Professionals from different professions seem to make different contributions. Moreover, differences exist between collaborative settings and healthcare subsectors. We conclude by proposing a research agenda to advance our understanding of these contributions in theoretical, methodological and empirical ways.
DOI: 10.6084/m9.figshare.8977430
title: grid.10854.38

description: Network Graphs for institution grid.10854.38 created for "What Does a University Look Like?" poster
DOI: 10.6084/m9.figshare.8977412
title: grid.40263.33

description: Network Graphs for institution grid.40263.33 created for "What Does a University Look Like?" poster
DOI: 10.6084/m9.figshare.8977289
title: Seedling_Survival_Data

description: This is species-specific seedling survival data along with site-specific degree days less than zero and temperature differential between maximum temperature of warmest month and minimum temperature of coldest month.
DOI: 10.6084/m9.figshare.8977046
title: Secondary structures of rfam group II introns

description: Structures of eukaryotic group II introns of RFAM RF00029 family
DOI: 10.6084/m9.figshare.8977046.v1
title: Secondary structures of rfam group II introns

description: Structures of introns group II of RFAM RF00029 family
DOI: 10.6084/m9.figshare.8977004
title: Supplementary Material for: Visit-to-Visit B-Type Natriuretic Peptide Variability during the Previous Year Has Independent Prognostic Value in Patients with Stable Chronic Heart Failure

description: <b><i>Background:</i></b> There is wide variability of visit-to-visit (V2V) B-type natriuretic peptide (BNP) in patients with chronic heart failure (CHF), even when they are stable. The prognostic significance of V2V-BNP variability has not been investigated. We aimed to test whether V2V-BNP variability during the stable period of CHF has prognostic value regardless of BNP level. <b><i>Methods:</i></b> In 278 stable outpatients (75 ± 10 years, 65% male) with CHF, we studied V2V-BNP variability, which was defined as the coefficient of variance of BNP values measured during 1 year before enrollment. All-cause death and rehospitalization due to HF were considered the primary endpoint. <b><i>Results:</i></b> The median V2V-BNP variability was 25.7% (IQR: 19.2–34.4%). During the follow-up period (median 3.2 years), 100 patients reached the endpoint and those with high V2V-BNP variability (≥25.7%) had a significantly higher rate of events (<i>p</i> = 0.001). CHF severity in terms of BNP level and MAGGIC risk score was not significantly different between those with high and low V2V-BNP variability. Multivariable analysis showed that high V2V-BNP variability was independently associated with increased event rates even after adjustment for other known prognostic predictors, including BNP (hazard ratio 1.90, <i>p</i> = 0.003), or for MAGGIC risk score and BNP (hazard ratio 1.72, <i>p</i> = 0.010). The hazard for the outcome consistently increased as V2V-BNP variability increased, with a marked increase up to about 30%. <b><i>Conclusions:</i></b> Even in the stable phase of CHF, V2V-BNP variability was associated with worse long-term outcomes, independent of BNP level.
DOI: 10.6084/m9.figshare.8977019
title: GDM raw data

description: Maternal microbiota is involved in many metabolic diseases. However, its role in the pathophysiology of Gestational diabetes mellitus (GDM) remains unclear. In this case-control study, 16S rRNA gene amplification technique was used to compare intestinal and oral microflora in late pregnant GDM patients (GDM + group) and normal pregnant women (GDM - group) during the same period.
DOI: 10.6084/m9.figshare.8977004.v1
title: Supplementary Material for: Visit-to-Visit B-Type Natriuretic Peptide Variability during the Previous Year Has Independent Prognostic Value in Patients with Stable Chronic Heart Failure

description: <b><i>Background:</i></b> There is wide variability of visit-to-visit (V2V) B-type natriuretic peptide (BNP) in patients with chronic heart failure (CHF), even when they are stable. The prognostic significance of V2V-BNP variability has not been investigated. We aimed to test whether V2V-BNP variability during the stable period of CHF has prognostic value regardless of BNP level. <b><i>Methods:</i></b> In 278 stable outpatients (75 ± 10 years, 65% male) with CHF, we studied V2V-BNP variability, which was defined as the coefficient of variance of BNP values measured during 1 year before enrollment. All-cause death and rehospitalization due to HF were considered the primary endpoint. <b><i>Results:</i></b> The median V2V-BNP variability was 25.7% (IQR: 19.2–34.4%). During the follow-up period (median 3.2 years), 100 patients reached the endpoint and those with high V2V-BNP variability (≥25.7%) had a significantly higher rate of events (<i>p</i> = 0.001). CHF severity in terms of BNP level and MAGGIC risk score was not significantly different between those with high and low V2V-BNP variability. Multivariable analysis showed that high V2V-BNP variability was independently associated with increased event rates even after adjustment for other known prognostic predictors, including BNP (hazard ratio 1.90, <i>p</i> = 0.003), or for MAGGIC risk score and BNP (hazard ratio 1.72, <i>p</i> = 0.010). The hazard for the outcome consistently increased as V2V-BNP variability increased, with a marked increase up to about 30%. <b><i>Conclusions:</i></b> Even in the stable phase of CHF, V2V-BNP variability was associated with worse long-term outcomes, independent of BNP level.
DOI: 10.6084/m9.figshare.8977046.v2
title: Secondary structures of rfam group II introns

description: Structures of introns group II of RFAM RF00029 family
DOI: 10.6084/m9.figshare.8976968
title: Supplementary Material for: Predictors of 90-Day Restart of Renal Replacement Therapy after Discontinuation of Continuous Renal Replacement Therapy, a Prospective Multicenter Study

description: <b><i>Background:</i></b> Restart of renal replacement therapy (RRT) after initial discontinuation of continuous RRT (CRRT) is frequently needed. The aim of the present study was to evaluate whether renal markers after discontinuation of CRRT can predict restart of RRT within 90 days. <b><i>Methods:</i></b> Prospective multicenter observational study in 90 patients, alive, still on the intensive care unit at day 2 after discontinuation of CRRT for expected recovery with urinary neutrophil gelatinase-associated lipocalin (NGAL) available. The endpoint was restart of RRT within 90 days. Baseline and renal characteristics were compared between outcome groups no restart or restart of RRT. Logistic regression and receiver operator characteristic curve analysis were performed to determine the best predictive and discriminative variables. <b><i>Results:</i></b> Restart of RRT was needed in 32/90 (36%) patients. Compared to patients not restarting, patients restarting RRT demonstrated a higher day 2 urinary NGAL, lower day 2 urine output, and higher incremental creatinine ratio (day 2/0). In multivariate analysis, only incremental creatinine ratio (day 2/0) remained independently associated with restart of RRT (OR 5.28, 95% CI 1.45–19.31, <i>p</i> = 0.012). The area under curve for incremental creatinine ratio to discriminate for restart of RRT was 0.76 (95% CI 0.64–0.88). The optimal cutoff was 1.49 (95% CI 1.44–1.62). <b><i>Conclusion:</i></b> In this prospective multicenter study, incremental creatinine ratio (day 2/0) was the best predictor for restart of RRT. Patients with an incremental creatinine ratio at day 2 of 1.5 times creatinine at discontinuation are likely to need RRT within 90 days. These patients might benefit from nephrological follow-up.